Abstract:
The current invention relates to an in vivo screening system where in a human pro-inflammatory cytokine promoter, tumor necrosis factor-a known for its role in the pathogenesis of both acute and chronic inflammatory diseases, was cloned into a luciferase-reporter vector and transfected into mouse skin by gene gun. Inhibition of the activation of TNF-a promoter by putative medicinal phytocompound/drug would indicate that the agent is a candidate for the treatment of skin related inflammatory diseases and possibly for systemic inflammatory conditions. By adopting this in vivo system, we successfully demonstrated that shikonins, phytocompounds from Lithospermum erythrorhizon inhibit the transcriptional activation of TNF-a and also provided the molecular basis for their inhibitory action. The current system has significant application for screening novel herbs/drugs for the prophylaxis or the treatment of human inflammatory diseases caused or mediated by tumor necrosis factor-alpha.
Fields of Application:
Pharmaceutical Industries: For fast identification and efficient quantitative molecular evaluation of anti-inflammatory medicinal herbs, phytocompounds and pharmaceutical drugs
Advantages when compared to the existing technologies:
1. Currently available screening technologies for anti-inflammatory agents are based on in vitro cell culture systems, where as the present invention uses an in vivo system which reflects the physiological conditions. 2. Current methods are focused on interfering with the secondary inflammatory mediators such as Cox-2, prostaglandins, leukotrienes etc. The present invention utilizes TNF-a, which has been identified as the cytokine at the apex of the pro-inflammatory cytokine cascade, and its production initiates and orchestrates the inflammatory response 3. Current methods are focused on inhibiting the undesirable effects of cytokine after its production by inactivation of TNF-a by monoclonal antibodies and blocking its receptors. The present invention helps to identify the compounds that interfere with the transcription of TNF-a, so that the later events never even come into being and the emergence of the disorder can thus be prevented at a very early phase.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
IP Status:know-how
